You are here

Article Text

Article menu
Download PDFPDF
Uterine Cancer
Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets
  1. Nora T. Kizer, MD*,
  2. Hatem Hatem, MD†,‡,
  3. Elizabeth K. Nugent, MD§,
  4. Gongfu Zhou, PhD∥,
  5. Kathleen Moore, MD§,
  6. Paul Heller, MD†,‡,
  7. David G. Mutch, MD* and
  8. Premal H. Thaker, MD*
  1. *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine and Siteman Cancer Center, Saint Louis, MO;
  2. †Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Atlantic Health System Hospitals at Simon Cancer Center, Morristown, NJ;
  3. ‡Overlook Hospital Summit, Summit, NJ;
  4. §Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stephenson Oklahoma Cancer Center, Oklahoma City, OK; and
  5. ∥Division of Biostatistics, Washington University School of Medicine and Siteman Cancer Center, Saint Louis, MO.
  1. Address correspondence and reprint requests to Nora T. Kizer, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine and Siteman Cancer Center, 4911 Barnes Jewish Hospital, 4th Floor Maternity Building, Saint Louis, MO 63110. E-mail: kizern{at}wudosis.wustl.edu; 800 North 1st Street, Springfield Clinic, Springfield, IL 62702. E-mail: nora.kizer{at}gmail.com.

Abstract

Objective This retrospective study evaluates the influence of serum platelet count on chemotherapy response rates among women with endometrial cancer.

Methods From 3 separate cancer centers, a total of 318 patients with endometrial cancer who received postoperative chemotherapy between June 1999 and October 2009 were retrospectively identified. Endometrioid, serous, clear cell, and carcinosarcoma histologies were included. Patients were classified as having an elevated platelet count if their serum platelet count was greater than 400 × 109/L at the time of initial diagnosis. Primary outcome was chemotherapy response, classified as either complete or partial/refractory. Secondary outcomes were disease-free and disease-specific survival. χ2 Test and Student t test were performed as appropriate. Kaplan-Meier curves and Cox proportional hazards models were used to assess serum platelet effect on survival.

Results There were 125 deaths, 76 recurrences, and 48 disease progressions. Of the total group, 53 (16.7%) were categorized as having an elevated platelet count. An elevated platelet count was associated with a lower chemotherapy response rate in univariate analysis (hazard ratio [HR], 2.8; 95% 95% confidence interval [CI], 1.46–5.38; P < 0.01). Multivariate analysis showed elevated platelets to be independently associated with decreased disease-free survival (HR, 2.24; 95% CI, 1.26–3.98; P < 0.01) but not disease-specific survival (HR, 1.03; 95% CI, 0.56–1.88, P = 0.93).

Conclusions Patients with endometrial cancer who have an elevated serum platelet count greater than 400 × 109/L may have lower chemotherapy response rates and are at increased risk for recurrence when compared with patients with a count within the reference range.

  • Chemotherapy response rates
  • Endometrial cancer
  • Elevated platelets

https://doi.org/10.1097/IGC.0000000000000453

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors wish to acknowledge the support of the Biostatistics Core, Siteman Comprehensive Cancer Center, and NCI Cancer Center Support Grant P30 CA091842.

    • This publication was made possible by Grant No. UL1 RR024992 from the National Center for Research Resources, a component of the National Institutes of Health.

    • The authors declare no conflicts of interest.